There is no single “best” injection for psoriasis, but the newest generation of biologics, particularly those targeting IL-23 and IL-17, consistently outperform older options in clinical trials for skin clearance, durability, and dosing convenience. If you have moderate-to-severe plaque psoriasis and your dermatologist is recommending an injectable biologic, the conversation will likely center on a handful of drugs that each have distinct advantages depending on what matters most to you.
How Psoriasis Injections Work
All injectable biologics for psoriasis work by blocking specific proteins in your immune system that drive skin inflammation. The differences come down to which protein they target, which affects how quickly they clear skin, how long they keep working, and how often you need a dose. The four main targets are TNF-alpha (the oldest class), IL-12/23, IL-17, and IL-23. Newer drugs targeting IL-23 and IL-17 generally produce higher rates of complete or near-complete skin clearance than the older TNF blockers.
Fastest Skin Clearance: IL-17 Blockers
If speed matters to you, IL-17 blockers like ixekizumab (Taltz) and secukinumab (Cosentyx) work faster than any other class. In head-to-head analyses, ixekizumab cut psoriasis severity in half in just 1.9 weeks, and a quarter of patients hit major clearance benchmarks by 2.4 weeks. Secukinumab was close behind, reaching those same milestones around the 3-week mark.
That rapid onset can be meaningful if you’re dealing with a severe flare or have an event coming up where visible plaques affect your quality of life. Both drugs require more frequent dosing during the first few months (weekly loading doses) before settling into a maintenance schedule.
Best Long-Term Staying Power
“Drug survival” measures how long patients stay on a biologic before it stops working or side effects force a switch. This matters because losing response and cycling through medications is one of the most frustrating parts of psoriasis treatment.
A large meta-analysis published in Frontiers in Medicine found that ustekinumab (Stelara), which blocks both IL-12 and IL-23, had the longest persistence at both 2 and 5 years of any biologic studied. Patients on ustekinumab were roughly twice as likely to still be on the drug at 2 years compared to those on older TNF blockers like etanercept or infliximab. Among the TNF blockers, adalimumab (Humira) held up best, with a 5-year survival rate of about 46%, compared to 36% for etanercept and 35% for infliximab.
The newer IL-23 blockers like risankizumab (Skyrizi) and guselkumab (Tremfya) haven’t been on the market long enough for robust 5-year drug survival data, but their clinical trial results for sustained clearance at 2 to 3 years are extremely strong, and many dermatologists expect them to match or beat ustekinumab’s durability.
Dosing Convenience
How often you give yourself an injection is a real quality-of-life factor. The options range from every two weeks to every three months:
- Adalimumab (Humira): Every 2 weeks, the most frequent maintenance schedule among common options.
- Secukinumab (Cosentyx): Every 4 weeks after an initial loading period.
- Ixekizumab (Taltz): Every 4 weeks after loading doses.
- Guselkumab (Tremfya): Every 8 weeks after two starter doses.
- Ustekinumab (Stelara): Every 12 weeks after two starter doses.
- Risankizumab (Skyrizi): Every 12 weeks after two starter doses (for plaque psoriasis).
Skyrizi and Stelara are the least burdensome, requiring only four or five injections per year once you’re past the initial phase. Tremfya falls in the middle at roughly six or seven per year. Humira, at 26 injections per year, demands the most commitment.
If You Also Have Joint Pain
About 30% of people with psoriasis eventually develop psoriatic arthritis, and if your joints are already stiff, swollen, or painful, that changes which injection makes the most sense. Not every biologic approved for skin psoriasis is equally effective for joints.
TNF blockers like adalimumab have decades of data supporting joint protection and are still widely used when arthritis is the primary concern. Among newer options, secukinumab, ixekizumab, guselkumab, and ustekinumab all carry FDA approvals for both psoriatic arthritis and plaque psoriasis. Risankizumab is approved for plaque psoriasis but not psoriatic arthritis, so if joint disease is part of your picture, your dermatologist or rheumatologist may steer you toward a drug that covers both.
Cost and Biosimilar Options
Biologic injections are expensive, often running tens of thousands of dollars per year before insurance. One way costs are starting to come down is through biosimilars, which are near-identical copies of brand-name biologics approved at lower prices.
Adalimumab now has multiple biosimilars on the market, which has brought down out-of-pocket costs for that drug significantly. Ustekinumab’s first biosimilar received FDA approval in May 2025, which should gradually lower pricing for that option as well. The newer IL-23 and IL-17 drugs don’t have biosimilars yet, so if cost is a major factor and your insurance coverage is limited, an adalimumab biosimilar may be the most accessible starting point, even if it isn’t the most effective option on paper.
Most biologic manufacturers also run copay assistance programs that can reduce your cost to under $50 per month if you have commercial insurance. If you’re uninsured or on a government plan, patient assistance programs from the manufacturer are worth exploring before assuming you can’t afford treatment.
How Dermatologists Choose
In practice, dermatologists weigh several factors when recommending an injection: how severe your psoriasis is, whether you have joint involvement, your insurance formulary, your comfort with injection frequency, and whether you’ve tried and failed other treatments. For someone with extensive skin disease and no joint problems, an IL-23 blocker like risankizumab or guselkumab is a common first pick because of the combination of high clearance rates, long-lasting results, and infrequent dosing. For someone who needs the fastest possible response, ixekizumab’s speed is hard to beat. For someone with both skin and joint disease, a TNF blocker or IL-17 blocker gives the broadest coverage.
The good news is that the current generation of psoriasis biologics is remarkably effective compared to what was available even a decade ago. Complete or near-complete skin clearance, once considered an ambitious goal, is now a realistic outcome with several of these drugs. The “best” injection is ultimately the one that matches your specific combination of symptoms, lifestyle, and insurance coverage.